86Y based PET radiopharmaceuticals: radiochemistry and biological applications - Wikidata - awgldk - TriplyDB

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

http://www.wikidata.org/entity/Q35250409

about

Mapping biological behaviors by application of longer-lived positron emitting radionuclides The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.Application of Immuno-PET in Antibody-Drug Conjugate Development

P2860

Q26824070-552C528F-952E-42D5-A8AD-E5E98C2EE9A5 Q33851546-B04ED24E-15EA-466D-8880-350055094805 Q36928870-C9E04136-1944-42F6-8867-F1F3C6495B6E Q38891132-F9E42545-E3DD-4009-9380-043E99A0CD65 Q40616136-32CC4684-70B0-40D8-88F5-5367F73B0BD4 Q41485304-4924C405-7698-4FD9-B6E1-06E7E80FD00E Q47588415-3CCD9B8C-3171-4695-88C2-F1E0920F569D Q58132996-8978CE1D-8EE1-489A-8A80-3C130929880D

P2860

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

http://www.wikidata.org/entity/Q35250409

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@ast

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@en

type

label

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@ast

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@en

prefLabel

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@ast

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@en

P1433

Q35250409-1FA4B2AB-3037-4A9B-9369-E431102E2181

P1476

Q35250409-109CEF9F-3DAC-424D-A03B-8234A2525971

P2093

Q35250409-D01D053D-6AE1-4990-9C8B-12F048F61B89

P2860

Q35250409-00D65FD4-542A-445A-A214-A7D27ED9FC16

Q35250409-02AE8B55-E66F-405F-AD07-59A5CE577423

Q35250409-069F422B-8207-48C5-8581-256EF4AE5EFB

Q35250409-07066545-667E-4508-891A-D32E5D3DE5C2

Q35250409-08E774B0-824D-430F-90C3-429B15275564

Q35250409-0D705E16-14F7-4550-B1F3-85B1D12E3BE4

Q35250409-0F452568-E5C8-4752-9274-483B8396F30C

Q35250409-221D6896-5817-4574-938D-87A5D8BCF1CD

Q35250409-2B7AA9F0-C175-4252-AF97-6C6951EF754E

Q35250409-32860A46-18E0-4B67-A73C-0B31CC1EC3AF

P304

Q35250409-DC7F2E89-AAD2-4477-AF7F-7C66C6303CE0

P31

Q35250409-7D7A43D5-CFAE-4DE8-9993-809118E62BD4

P356

Q35250409-10BDC77B-D3C2-4386-A4FD-CE24A2DC4DD8

P433

Q35250409-DA40655B-6A07-4B29-B5A2-2F3270FCD44E

P478

Q35250409-23DC88ED-7FE6-47F8-9CA0-ED30E6CA0861

P50

Q35250409-4EA6AA71-BFBB-4F45-9763-D05BA39E555E

P577

Q35250409-1DF7194A-DBF3-4136-A3FF-95BA86B6AB9A

P5875

Q35250409-93461780-1932-4A2B-99AC-4CD5F94D1A25

P698

Q35250409-D37D5548-CE5F-4838-A549-1F53105091A3

P932

Q35250409-1841CDA2-7C94-42D0-85DD-8FEE8FAC43CA

P356

157340611796799249

P1433

Medicinal Chemistry

P1476

86Y based PET radiopharmaceuticals: radiochemistry and biological applications

@en

P2093

Martin W Brechbiel

http://www.w3.org/2001/XMLSchema#string

P2860

Decay data and production yields of some non-standard positron emitters used in PET.

Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.

Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma

PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.

Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies.

P304

380-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/157340611796799249

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51450209

http://www.w3.org/2001/XMLSchema#string

P698

21711222

http://www.w3.org/2001/XMLSchema#string

P932

3184346

http://www.w3.org/2001/XMLSchema#string